Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
A new subscription option for Prime members marks an "important step" for Amazon's grocery strategy, according to one analyst.
The wait for Tesla results is on as investors look to Big Tech earnings to buoy stocks.